3SOF

Maybe it's running on this news.

https://us.etrade.com/e/t/invest/Story?ID=STORYID%3Detrade_2005_11_18_eng-etrade_cbs2_market_watch_eng-etrade_cbs2_market_watch_65EE52E9-30B1-4F79-B8CB-EAF738EBA4EB&provider=PRNewswire

NASI Has to be next

NASI, looks to be oversold @ 2.00. I think a lot people sold because they were anticipating the China sales news to be released before 10-31-05.There is still no news.I bought more yesterday and today. NASI has a tiny float,14 mil.So when and if there is good news it will fly.

IMRT-enabled linac. nomosSTAT is expected to be available for shipment early in 2006, following FDA 510(k) approval.

Earnings and cc on....1-09-06
it will host an investor conference call to review its fourth quarter and fiscal year 2005 financial results and latest corporate developments,

http://biz.yahoo.com/bw/051209/20051209005101.html?.v=1

I'm done buying now.

Bid-2.26

Ask-2.30

Keep an eye on NASI this week, might make a nice run into earnings and cc  on 1-09-06.

CC- (live today at 4:30 pm ET)
http://biz.yahoo.com/cc/1/63411.html

North American Scientific Reports Record Revenues of $32.2 Million for Fiscal 2005
1/9/2006 4:05et
CHATSWORTH, Calif., Jan 09, 2006 (BUSINESS WIRE) -- North American Scientific, Inc. (NASI):


-- Company Records $40.2 Million Impairment Charge For NOMOS Goodwill And Intangible Assets

-- Company Ships Serial Tomotherapy Products to China

North American Scientific, Inc. (NASI) today announced financial results for its fourth quarter and fiscal year ended October 31, 2005.

"Fiscal year 2005 was very challenging for our Company as we integrated NOMOS and realigned our organization to capitalize on future growth opportunities," said L. Michael Cutrer, President and CEO. "Due to delays in new product introductions and international registrations, the fourth quarter results were disappointing, but we remain confident that our new products and new markets will allow us to grow our revenue base.

"During the fiscal fourth quarter, we introduced our new serial tomotherapy advanced treatment solution, nomosSTAT(TM), which integrates our core serial tomotherapy delivery products with user interface controls both inside and outside the treatment room," continued Mr. Cutrer. "Interest in this affordable, new system appears to be growing, and we anticipate sales later in the year following the 510(k) approval from the Food and Drug Administration.

"In addition, we expect to continue our international expansion in Europe and Asia," Mr. Cutrer continued. "During our fiscal fourth quarter, we received approval from the People's Republic of China State Food and Drug Administration (SFDA) to sell our PEACOCK(R) product, a serial tomotherapy system designed for the treatment of various types of cancer with intensity modulated radiation therapy (IMRT). We shipped and delivered our first order following SFDA approval in our fiscal 2006 first quarter, and are pleased with the growth opportunities that this region represents. We are also pleased with improvement in brachytherapy sales in the second half of fiscal 2005, and look forward to new product introductions early in fiscal 2006. While last year was challenging, we believe we are poised for growth in 2006 and we are excited about our opportunities both domestically and internationally."

LINK-TO earnings
http://biz.yahoo.com/bw/060109/20060109005874.html?.v=1

Interesting volume spikes recently....

Interesting chart 

(NASI)
Opens Higher Following First
Procedure w/ClearPath-HDR
Shares of North American Scientific, Inc. (NASI) got an opening
boost in Friday's session after it announced the use of its
ClearPath-HDR device in a patient for the first time. For use in
Accelerated Partial Breast Irradiation (APBI) treatment plans,
ClearPath-HDR combines the ease-of-use benefits of balloon brachytherapy
products with the customized dose planning benefits of the multi-catheter
brachytherapy procedure into one device. This combination also allows doctors to take advantage
of a shorter five-day APBI treatment plan, compared with the six to eight weeks required for
external beam treatment plans. In addition, ClearPath is implanted through a single incision and
is designed to minimize radiation exposure of nearby healthy tissue. The Company estimates that
the ClearPath systems will serve an addressable market of more than $500 million.
"This first human clinical experience with ClearPath-HDR is a significant milestone," said John
B. Rush, President and Chief Executive Officer of North American Scientific. "We believe our
ClearPath technology is favorably distinguished from other products on the market, including balloon
brachytherapy, interstitial catheters and external beam radiation due to its important benefits
to the patient and physician. ClearPath can make APBI a possibility for more patients that were
previously not considered good candidates for treatment with balloon brachytherapy products
due to breast size and/or tumor location. With its ease-of-use, functionality and few treatment
limiting requirements we believe ClearPath has the potential to encourage the use of APBI, a less
invasive, more focused treatment option for many afflicted with breast cancer."
North American Scientific manufactures and sells products for the radiation oncology market. Its
Prospera(R) brachytherapy seeds and SurTRAK(TM) needles and strands are used primarily in
the treatment of prostate cancer. The Company also develops and markets brachytherapy accessories
used in the treatment of disease and calibration sources used in medical, environmental,
research and industrial applications.
The new ClearPath-HDR device for treatment of breast cancer is, like its competitors, designed to
connect to a source of high-dose-rate radiation which is administered in a specially shielded room
in a hospital. It faces competition from Cytyc Corp. (CYTC), SenoRx, Inc. (SENO) and Cianna
Medical. The MammoSite RTS device from Cytyc, currently the market leader, uses a balloon and
catheter system to place the radiation source directly into the post-lumpectomy cavity. A device
developed by SenoRx also uses a balloon and catheter system to deliver the radiation dose. The
SAVI device manufactured by Cianna Medical does not use a balloon and is comprised of an
expandable bundle of catheters.
The primary competitors in the brachytherapy seed business include: Nycomed Amersham PLC
(through its control of Oncura), C.R Bard, Inc. (BCR), and Theragenics Corporation (TGX). Several
additional companies currently sell brachytherapy seeds as well. SurTRAK strands and
needles are subject to competition from a number of companies, including Worldwide Medical
Technologies, Inc.
For the third quarter ended July 31, 2007. the Company reported revenues of $3.4 million and a
net loss from continuing operations of $0.10 per share, compared with revenues of $3.0 million
and a net loss in 2006 of $0.10 per share. As of July 31, 2007, the Company has an accumulated
deficit of $144.6 million; cash and cash equivalents of $1.8 million; borrowings under a line of
credit of $1.4 million; and no long-term debt.
The Company recently divested its NOMOS Radiation Oncology business, which develops and
markets IMRT/IGRT products used during external beam radiation therapy for the treatment of
cancer. The purchase price was $500,000 cash at closing, plus assumption of certain obligations
and liabilities.The divestiture allows the Company to utilize financial resources for the marketing
and development of its brachytherapy products.
A notice from The Nasdaq Stock Market indicated last week that the Company does not comply
with the minimum $10 million stockholders' equity requirement. In addition, the Company does
not comply with the minimum $50 million market value of listed securities for continued listing.
The Company will submit a plan that it believes will allow it to achieve and sustain compliance